Last quarter (Q4 2022), Neuroscientific Biopharmaceuticals Ltd.'s total revenue was $―, a decrease of ― from previous quarter. In Q4, Neuroscientific Biopharmaceuticals Ltd.'s net income was $―. See Neuroscientific Biopharmaceuticals Ltd.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jun 22	Jun 21	Jun 20	Jun 19
Total Revenue	$ ―	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ ―	$ ―
Gross Profit	$ ―	$ ―	$ ―	$ ―	$ ―
Operating Expense	$ ―	$ 10.50M	$ 4.22M	$ 2.94M	$ 1.78M
Operating Income	$ ―	$ -10.50M	$ -4.22M	$ -2.94M	$ -1.78M
Net Non Operating Interest Income Expense	$ ―	$ 68.45K	$ 27.58K	$ 32.32K	$ 85.44K
Other Income Expense	$ ―	$ ―	$ 1.02M	$ 40.54K	$ 33.85K
Pretax Income	$ ―	$ -10.44M	$ -3.18M	$ -2.87M	$ -1.66M
Tax Provision	$ ―	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -10.44M	$ -3.18M	$ -2.87M	$ -1.66M
Basic EPS	$ ―	$ -0.07	$ -0.02	$ -0.04	$ -0.02
Diluted EPS	$ ―	$ -0.07	$ -0.02	$ -0.04	$ -0.02
Basic Average Shares	$ ―	$ 143.47M	$ 143.47M	$ 78.38M	$ 71.53M
Diluted Average Shares	$ ―	$ 143.47M	$ 143.47M	$ 78.38M	$ 71.53M
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income From Continuing And Discontinued Operation	$ ―	$ -10.44M	$ -3.18M	$ -2.87M	$ -1.66M
Normalized Income	$ ―	$ -10.44M	$ -3.18M	$ -2.87M	$ -1.66M
Interest Expense	$ ―	$ ―	$ 63.00	$ 3.42K	$ ―
EBIT	$ ―	$ -10.50M	$ -3.18M	$ -2.87M	$ -1.78M
EBITDA	$ ―	$ -10.44M	$ -3.12M	$ -2.81M	$ -1.72M

Currency in USD

Neuroscientific Biopharmaceuticals Ltd. Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing